Edesa reports fiscal Q3 2026 results, readies EB06 vitiligo trial and ARDS data

Edesa Biotech reported financial results for the three and nine months ended June 30, 2026 on August 13, 2026. The company finished preparations during the quarter for a Phase 2 study of EB06, an anti-CXCL10 monoclonal antibody, in patients with moderate-to-severe nonsegmental vitiligo.¹ After quarter-end, Edesa began activating its first investigational sites and said it expects patient recruitment to start in the coming weeks in Canada, with additional countries to follow depending on regulatory clearance and administrative filings.¹

On the respiratory side, Edesa ran further exploratory analyses looking at paridiprubart's effect in ARDS patients who also had acute kidney injury.¹ In that subgroup, paridiprubart combined with standard of care was linked to significant reductions in mortality, alongside matching improvements in the kidney-focused MAKE30 composite endpoint.¹ Edesa said it continues to weigh regulatory pathways in major markets for the drug and is pursuing strategic discussions to advance the program.¹

CEO Par Nijhawan called the quarter an operational turning point given the vitiligo trial progress and said the AKI findings support outreach to potential partners for late-stage development and commercialization, according to the release. CFO Peter Weiler said spending is shifting from preparatory work to trial execution as EB06's Phase 2 study becomes the priority, while regulatory, manufacturing and business-development work continues on paridiprubart.

At June 30, 2026, Edesa had cash and cash equivalents of $10.3 million and working capital of $6.9 million.¹ Net loss for the quarter was $5.4 million, or $0.60 per share, versus $1.7 million, or $0.25 per share, a year earlier¹, with the increase tied largely to manufacturing and preparatory spending on the EB06 study. Management is set to appear at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 12-13, 2026.¹